Co-expression of estrogen receptor α and Apolipoprotein D in node positive operable breast cancer – possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients

References

• Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006; 354: 270–82
   PubMed Web of Science ®Google Scholar
• Bernardi, D, Errante, D, Galligioni, E, Crivellari, D, Bianco, A, Salvagno, L, , et al. Treatment of breast cancer in older women. Acta Oncol Epub [cited September 26 2007] PubMed; PMID 17899452.
   Google Scholar
• Pierga JY, Girre V, Laurence V, Asselain B, Dieras V, Jouve M, et al. Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age. Breast 2004; 13: 369–75
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998;351:1451–67.
   PubMed Web of Science ®Google Scholar
• Balbin M, Freije JM, Fueyo A, Sanchez LM, Lopez-Otin C. Apolipoprotein D is the major protein component in cyst fluid from women with human breast gross cystic disease. Biochem J 1990; 271: 803–7
   PubMed Web of Science ®Google Scholar
• Søiland H, Søreide K, Janssen EA, Kørner H, Baak JP, Søreide JA. Emerging concepts of Apolipoprotein D with possible implications for breast cancer. Cell Oncol 2007; 29: 195–209
   PubMedGoogle Scholar
• Do Carmo S, Levros LC, Jr, Rassart E. Modulation of Apolipoprotein D expression and translocation under specific stress conditions. Biochim Biophys Acta 2007; 1773: 954–69
   PubMedGoogle Scholar
• Simard J, Dauvois S, Haagensen DE, Levesque C, Merand Y, Labrie F. Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: A new marker of steroid action in breast cancer. Endocrinology 1990; 126: 3223–31
   PubMed Web of Science ®Google Scholar
• Harding C, Osundeko O, Tetlow L, Faragher EB, Howell A, Bundred NJ. Hormonally-regulated proteins in breast secretions are markers of target organ sensitivity. Br J Cancer 2000; 82: 354–60
   PubMedGoogle Scholar
• Lea OA. Binding properties of progesterone-binding cyst protein, PBCP. Steroids 1988; 52: 337–38
   PubMedGoogle Scholar
• Søiland, H, Janssen, EAM, Kørner, H, Varhaug, JE, Skaland, I, Gudlaugson, E, , et al. Apolipoprotein D predicts adverse outcome in patients over 70 years with operable breast cancer. Breast Cancer Res Treat Epub [cited March 11 2008]. PubMed; PMID 18330697.
   Google Scholar
• Søreide JA, Lea OA, Anda O, Skarstein A, Varhaug JE, Kvinnsland S. Progesterone-binding cyst protein (PBCP) in operable breast cancer: Correlations with prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Anticancer Res 1991; 11: 601–5
   PubMed Web of Science ®Google Scholar
• Gundersen S, Hannisdal E, Søreide JA, Skarstein A, Varhaug JE. Adjuvant tamoxifen for pre- and postmenopausal women with estrogen receptor positive, node positive breast cancer: A randomized study. Breast Cancer Res Treat 1995; 36: 49–53
   PubMedGoogle Scholar
• Tavassoli, FA, Devilee, P. Pathology and genetics of tumours of the breast and female genital organs. In: World Health Organization Classification of Tumours, Lyon: IARC Press; 2003. p 9–112.
   Google Scholar
• Sobin, LH, Wittekind, C. Breast tumors. In: TNM classifications of malignant tumors. 6th ed. International Union Against Cancer (UICC). Hoboken, New Jersey: John Wiley & Sons; 2002. p 131–142.
   Google Scholar
• Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV, Vermorken JB, et al. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 2005; 23: 5993–6001
   Google Scholar
• Søiland H, Skaland I, Janssen EA, Kørner H, Varhaug JE, Søreide JA, et al. Comparison of Apolipoprotein D determination methods in breast cancer. Anticancer Res 2008; 28: 673–80
   PubMedGoogle Scholar
• Norwegian Breast Cancer Group (NBCG), www.nbcg.no. [updated February 1 2008; cited May 6 2008]. Available from:, http://www.nbcg.no/nbcg.blaaboka.html#Anchor-13-37516.
   Google Scholar
• Diez-Itza I, Vizoso F, Merino AM, Sanchez LM, Tolivia J, Fernandez J, et al. Expression and prognostic significance of Apolipoprotein D in breast cancer. Am J Pathol 1994; 144: 310–20
   PubMed Web of Science ®Google Scholar
• Do Carmo S, Seguin D, Milne R, Rassart E. Modulation of Apolipoprotein D and Apolipoprotein E mRNA expression by growth arrest and identification of key elements in the promoter. J Biol Chem 2002; 277: 5514–23
   PubMedGoogle Scholar
• Herynk MH, Parra I, Cui Y, Beyer A, Wu MF, Hilsenbeck SG, et al. Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer. Clin Cancer Res 2007; 13: 3235–43
   PubMedGoogle Scholar
• Harrell JC, Dye WW, Harvell DM, Pinto M, Jedlicka P, Sartorius CA, et al. Estrogen insensitivity in a model of estrogen receptor positive breast cancer lymph node metastasis. Cancer Res 2007; 67: 10582–91
   PubMed Web of Science ®Google Scholar
• Zilli, M, Grassadonia, A, Tinari, N, Di Giacobbe, A, Gildetti, S, Giampirtro, J, , et al. Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer. Biochim Biophys Acta 2008. E-pub: PMID:18804516.
   Google Scholar
• Gjerde J, Kisanga ER, Hauglid M, Holm PI, Mellgren G, Lien EA. Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry. J Chromatogr A 2005; 1082: 6–14
   PubMed Web of Science ®Google Scholar